Back to Trades
Sell4
Kiniksa Pharmaceuticals International, plc
KNSA
Total Value
$7.8M
Net $4.6M sold
Sales
$4.6M
2 transactions
Grants
$11.8K
1 transaction
Company Information
- Company Name
- Kiniksa Pharmaceuticals International, plc
- Ticker Symbol
- KNSA
- CIK
- 0001730430
Insider Information
- Name
- Tessari Eben
- Role
- Insider
- Location
- LONDON, X0
Filing Details
- Filing Date
- Aug 7, 2025
- Transaction Date
- Jul 15, 2025
- Accession Number
- 0001415889-25-021271
- Form Type
- 4
- Net Trading Amount
- -$4.6M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 15, 2025 | Class A Ordinary Share | 752 | $15.63 | Grant/Award | $11.8K |
| Aug 5, 2025 | Class A Ordinary Share | 38,928 | $10.36 | Exercise | $403.3K |
| Aug 5, 2025 | Class A Ordinary Share | 30,444 | $12.97 | Exercise | $394.9K |
| Aug 5, 2025 | Class A Ordinary Share | 32,710 | $11.10 | Exercise | $363.1K |
| Aug 5, 2025 | Class A Ordinary Share | 25,896 | $11.97 | Exercise | $310.0K |
| Aug 5, 2025 | Class A Ordinary Share | 10,636 | $10.76 | Exercise | $114.4K |
| Aug 5, 2025 | Class A Ordinary Share | 138,064 | $33.20 | Sale | $4.6M |
| Aug 5, 2025 | Class A Ordinary Share | 550 | $33.90 | Sale | $18.6K |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Aug 5, 2025 | Derivative | 38,928 | $10.36 | Exercise | $403.3K |
| Aug 5, 2025 | Derivative | 30,444 | $12.97 | Exercise | $394.9K |
| Aug 5, 2025 | Derivative | 32,710 | $11.10 | Exercise | $363.1K |
| Aug 5, 2025 | Derivative | 25,896 | $11.97 | Exercise | $310.0K |
| Aug 5, 2025 | Derivative | 10,636 | $10.76 | Exercise | $114.4K |
Footnotes
- (F1)The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2025 to July 15, 2025. The acquisition of these shares was exempt pursuant to Rule 16B-3(e).
- (F2)This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
- (F3)This transaction was executed in multiple trades through a broker-dealer at prices ranging between $32.83 and $33.82. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- (F4)This transaction was executed in multiple trades through a broker-dealer at prices ranging between $33.83 and $33.98. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- (F5)The option is fully vested and exercisable.
- (F6)The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021.
- (F7)The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.
- (F8)The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.
- (F9)The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.